GE HealthCare Debuts New PET/MRI System at SNMMI Conference

Offering a variety of reported technological advances to facilitate the diagnosis of conditions such as Alzheimer’s disease and prostate cancer, the Signa PET/MR Air system (GE HealthCare) will be launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

The Signa PET/MR Air system combines the high sensitivity of positron emission tomography (PET) with the anatomical precision offered by magnetic resonance imaging (MRI) in one device, according to GE HealthCare. The company said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the Signa PET/MR Air system may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases.

Other features of the Signa PET/MR Air system include the Time-of-Flight (TOF) PET detector and MotionFree Brain PET. Addressing patient motion during exams without external tracking devices, MotionFree Brain PET enables consistent image quality, which reduces repeat scans and may potentially improve diagnostic accuracy for challenging patients, according to the company. GE HealthCare added that the sensitivity of the ToF PET detector can detect adverse effects in a single scan and provide insights into disease progression.

“Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer’s disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring,” noted Jie Xue, president and CEO of MR at GE HealthCare. “We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”